Abcam Plc (ABC) Stock Rating Reaffirmed by Peel Hunt

Abcam Plc (LON:ABC)‘s stock had its “hold” rating reissued by Peel Hunt in a research note issued to investors on Friday. They currently have a GBX 750 ($9.26) price target on the stock. Peel Hunt’s price objective indicates a potential downside of 11.45% from the company’s previous close.

Several other equities analysts have also commented on ABC. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a GBX 678 ($8.37) price target on shares of Abcam Plc in a research report on Wednesday, January 4th. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 870 ($10.74) price target on shares of Abcam Plc in a research report on Tuesday, January 10th. Finally, Panmure Gordon reaffirmed a “sell” rating and set a GBX 640 ($7.90) price target on shares of Abcam Plc in a research report on Tuesday, January 10th. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. Abcam Plc has an average rating of “Hold” and an average price target of GBX 726 ($8.97).

Analyst Recommendations for Abcam Plc (LON:ABC)

Shares of Abcam Plc (LON:ABC) opened at 839.00 on Friday. The stock’s market capitalization is GBX 1.70 billion. Abcam Plc has a 52-week low of GBX 580.50 and a 52-week high of GBX 948.00. The stock’s 50 day moving average is GBX 865.97 and its 200 day moving average is GBX 831.16.

The business also recently declared a dividend, which will be paid on Thursday, April 13th. Investors of record on Thursday, March 16th will be given a dividend of GBX 2.83 ($0.03) per share. This represents a yield of 0.31%. The ex-dividend date is Thursday, March 16th.

Your IP Address:

About Abcam Plc

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply